

C-CAMP, IHMA to develop innovative solutions for combating AMR

04 December 2020 | News

C-CAMP and IHMA will jointly facilitate microbiology-related studies for clinical trials, surveillance studies, mentorship programs



In a major boost to its existing entrepreneurship and acceleration programs in antimicrobial resistance (AMR) domain, Centre for Cellular and Molecular Platforms or C-CAMP has signed a pact with the Internal Health Management Associates, IHMA to bring world-class platform technologies including phage analysis to Indian drug discovery startups and Indian diagnostics startups in AMR arena. The pact will also bring exposure to global regulatory standards for building more globally competitive and globally relevant innovations from India.

IHMA has supported anti-infective and diagnostic development studies for over 25 years. IHMA has laboratory facilities in US, Switzerland and China plus a business office in India.

By the agreement, C-CAMP and IHMA will jointly facilitate microbiology-related studies for clinical trials, surveillance studies, mentorship programs and other activities to promote new drug and vaccine discovery in the area of anti-infectives and new-age diagnostic device development to address AMR.

C-CAMP, India's premier bioresearch & innovation hub with a portfolio spread over the entire life sciences spectrum, has seen rapid advances being made in the AMR innovation space in India. C-CAMP's AMR programs are designed to identify and accelerate commercialization of innovations in AMR, whereas its Analytical and Technology Platforms are accessible to researchers in a service mode. C-CAMP marquee start-ups such as Bugworks have risen to international prominence with an exciting pipeline of next generation broad-spectrum antimicrobials.

C-CAMP is also a member of the CARB-X Global Accelerator Network, a league of 10 top organizations combating AMR across USA and Europe. IHMA is a global microbiology research laboratory that provides extensive services to support the pharmaceutical industry. Their portfolio comprises 250+ healthcare institutions globally that can be leveraged by India's leading antibiotic developers to carry out clinical trials and surveillance studies. IHMA has vast experience with the identification and susceptibility testing of bacterial species. Moreover, IHMA has a diverse library of clinically relevant phenotypically and genotypically characterized bacterial and fungal isolates that can be used to assist with profiling of anti-

infective agents during development.